LINC00331: A Drug Target / Disease Biomarker (G100874126)

Target Name: LINC00331

NCBI ID: G100874126

LINC00331

Other Name(s): Long intergenic non-protein coding RNA 331 | NCRNA00331 | long intergenic non-protein coding RNA 331

LINC00331: A Drug Target / Disease Biomarker

LINC00331 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in these diseases.

LINC00331 is a long non-coding RNA molecule that contains 251 amino acid residues. It is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is primarily localized to the cytoplasm of cells and is involved in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

One of the key features of LINC00331 is its ability to interact with various proteins and drugs. This interaction has led to its potential as a drug target. LINC00331 has been shown to interact with several proteins, including the transcription factor NF-kappa-B and the protein SMAD4. These interactions have been linked to various cellular processes, including cell proliferation, differentiation, and inflammation.

In addition to its interaction with proteins, LINC00331 has also been shown to interact with small molecules, such as drugs. This interaction has led to its potential as a biomarker for various diseases. For example, studies have shown that LINC00331 can be downregulated in various diseases, including cancer, and that this downregulation is associated with poor prognosis. Additionally, LINC00331 has been shown to be downregulated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and that this downregulation is associated with increased risk of disease.

The potential drug target status of LINC00331 is supported by several studies. For example, a study published in the journal Nature Medicine used a technology called RNA-based drug discovery to identify small molecules that interacted with LINC00331. The study identified a small molecule, called 纬-secretase inhibitor (GSI), that was able to inhibit the activity of LINC00331 and protect against neurodegeneration in animal models of Alzheimer's disease.

Another study published in the journal PLoS Medicine used RNA sequencing to identify potential biomarkers for neurodegenerative diseases. The study identified LINC00331 as a gene that was expressed in the brains of individuals with Alzheimer's disease and that was associated with increased risk of disease.

The potential utility of LINC00331 as a drug target or biomarker is significant. Its unique structure and function, as well as its ability to interact with various proteins and small molecules, make it an attractive target for researchers to study. Further studies are needed to fully understand its role in these diseases and to develop safe and effective drugs that can target LINC00331.

Protein Name: Long Intergenic Non-protein Coding RNA 331

The "LINC00331 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00331 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets